MIP Diagnostics raises £1.5m investment

MIP Diagnostics, a UK based life sciences group, has raised £1.5 million investment to help advance its development of synthetic alternatives to antibodies. The investment will fund the team’s expansion, set up new production facilities and help with developing internal products to be sold under licence.
Chief executive Dr Adrian Kinkaid said “Our technology has proven to be highly effective in a range of applications and with diverse targets from small molecules to viruses. This investment enables us to respond to the growing demand by increasing headcount and moving to new laboratories. I am particularly pleased that we can now start to develop our own high-performance MIPs to meet the needs of recognized high-value markets. These assets will be licensed to our partners in due course.”